Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P56851 (
epididymal
)
11,273
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Obesity is an important independent risk factor for type 2 diabetes, cardiovascular diseases and many other chronic diseases. Adipose tissue inflammation is a critical link between obesity and insulin resistance and type 2 diabetes and a contributor to disease susceptibility and progression. The objective of this study was to determine the role of
response gene to complement 32
(
RGC32
) in the development of obesity and insulin resistance. WT and
RGC32
knockout (Rgc32(-/-) (Rgcc)) mice were fed normal chow or high-fat diet (HFD) for 12 weeks. Metabolic, biochemical, and histologic analyses were performed. 3T3-L1 preadipocytes were used to study the role of
RGC32
in adipocytes in vitro. Rgc32(-/-) mice fed with HFD exhibited a lean phenotype with reduced
epididymal
fat weight compared with WT controls. Blood biochemical analysis and insulin tolerance test showed that
RGC32
deficiency improved HFD-induced dyslipidemia and insulin resistance. Although it had no effect on adipocyte differentiation,
RGC32
deficiency ameliorated adipose tissue and systemic inflammation. Moreover, Rgc32(-/-) induced browning of adipose tissues and increased energy expenditure. Our data indicated that
RGC32
plays an important role in diet-induced obesity and insulin resistance, and thus it may serve as a potential novel drug target for developing therapeutics to treat obesity and metabolic disorders.
...
PMID:RGC32 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice. 2538 71